Form 8-K

8-K — Envoy Medical, Inc.

Accession: 0001213900-26-035483

Filed: 2026-03-27

Period: 2026-03-23

CIK: 0001840877

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0283065-8k_envoy.htm (Primary)

EX-99.1 — PRESS RELEASE DATED MARCH 23, 2026 (ea028306501ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0283065-8k_envoy.htm · Sequence: 1

false

0001840877

2026-03-23

0001840877

COCH:ClassCommonStockParValue0.0001PerShareMember

2026-03-23

0001840877

COCH:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember

2026-03-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 23, 2026

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-40133

86-1369123

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

4875 White Bear Parkway

White Bear Lake, MN

55110

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (877) 900-3277

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.0001 per share

COCH

The Nasdaq Stock Market LLC

Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share

COCHW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On March 23, 2026, Envoy Medical, Inc. (the “Company”),

issued a press release regarding the Company’s financial results for its fourth fiscal quarter and fiscal year ended December 31,

2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02, including the accompanying exhibit,

is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not

be incorporated into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation

language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number

Description

99.1

Press Release dated March 23, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENVOY MEDICAL, INC.

March 27, 2026

By:

/s/ Robert Potashnick

Robert Potashnick

Interim Chief Financial Officer

EX-99.1 — PRESS RELEASE DATED MARCH 23, 2026

EX-99.1

Filename: ea028306501ex99-1.htm · Sequence: 2

Exhibit 99.1

Envoy Medical Reports Full Year 2025 Financial

Results

Received FDA approval to expand fully implanted

Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage

Strengthened balance sheet by extinguishing

$32 million in debt

Subsequent to year-end, closed on transformational

capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-of-its-kind

fully implanted cochlear implant

White Bear Lake, Minnesota – March 23, 2026 – Envoy

Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health company pioneering fully

implanted hearing solutions, today announced its corporate and financial results for the full year ended December 31, 2025, as well as

other subsequent events.

Corporate and Financial Highlights for 2025:

● Received

FDA Approval to Expand Its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data

● Extinguished

over $32 Million in Debt, Strengthening Balance Sheet

● Completed

First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant

● Achieved

Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial

Highlights Subsequent to 2025 Year End:

● Completed

enrollment of a 56-patient U.S. pivotal trial for the fully implanted Acclaim® Cochlear Implant

● Strengthened

balance sheet with up to $78M public offering ($30M received, $48M potential from warrants)

● Expanded

IP portfolio to 47 patents across North America, Europe, Asia, and Australia as of Feb. 20, 2026

Brent Lucas, CEO of Envoy Medical, commented: “We

are extremely proud of the significant progress we made as a company in 2025, which included the FDA approval to expand our pivotal clinical

trial to its final stage.

We were also, on the financial side,

able to extinguish over $32 million in debt to create a much stronger balance sheet. In addition, we continued to further expand our global

patent portfolio as a leading fully implanted hearing technology company.

The momentum from 2025 has set the

stage for an exceptional start to 2026. In February, we closed a transformational capital raise that included established institutional

healthcare investors and existing shareholders. In March, we announced complete enrollment of our pivotal clinical trial for investigational

fully implanted Acclaim cochlear implant. We are now in a strengthened position as we continue to gather data and look forward to submitting

our PMA application to the FDA.

The future is bright for Envoy Medical

as we aim to revolutionize hearing health by providing fully implanted solutions to address the unmet needs of millions of individuals

worldwide. We hope you join us on this meaningful and exciting journey.”

Financial Results for the Year Ended December 31, 2025 (dollars

in thousands):

Net Revenue was $241 as of December 31, 2025 compared to $225 for year

ended December 31, 2024. The increase of $16 was primarily driven by the sales of the Esteem® FI-AMEI implant and related replacement

components.

Cost of goods sold increased $132 compared to the year ended December

31, 2024. The increase is primarily due to an increase in scrap and non-recurring expenses of $190, which was partially offset by lower

fees for third-parties performing work related to our products of $77.

R&D expenses, which include expenses related to the Acclaim pivotal

clinical trial, increased by $2,307 for the year ended December 31, 2025 compared to the year ended December 31, 2024. This increase mainly

reflects additional clinical trial expense during enrollment.

Sales and marketing expenses of December 31, 2025 were $1,220 compared

to $1,734 for the year ended December 31, 2024 a decrease of $514. The decrease is primarily due to a reduction of legal fees associated

with reimbursement work for the Esteem FI-AMEI product.

General and administrative expenses increased $1,105 to $7,931 for

the year ended December 31, 2025 compared to $6,826 for the year ended December 31, 2024. The increase was primarily due to severance

costs associated with the former Chief Financial Officer and increased consulting expenses.

As of December 31, 2025, cash was approximately $3.7 million.

The Acclaim® cochlear implant received Breakthrough Device Designation

from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the

trial, visit www.envoymedical.com/acclaim-pivotal.

To be added to the Envoy Medical email distribution list, please email

Envoy@kcsa.com with COCH in the subject line.

About Envoy Medical, Inc.

Envoy Medical (NASDAQ: COCH) is a

hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind,

fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available

in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated

to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

About the Fully Implanted Acclaim® Cochlear Implant

We believe

the fully implanted Acclaim Cochlear Implant (“Acclaim CI”) is a first-of-its-kind hearing device. Envoy Medical’s fully implanted

technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe to profound sensorineural

hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed

adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation

from the U.S. Food and Drug Administration (FDA) in 2019.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational

device. Limited by Federal (or United States) law to investigational use.

About the Esteem® Fully Implanted Active Middle Ear Implant

(FI-AMEI)

The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device

for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear’s natural

anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear

canal for it to function. Unlike hearing aids, you never put it on or take it off. You can’t lose it. You don’t clean it. The Esteem

FI-AMEI hearing implant offers true 24/7 hearing.

* Once activated, the external Esteem FI-AMEI Personal Programmer

is not required for daily use.

Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Additional Information and Where to Find It

Copies of the documents

filed by Envoy Medical with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov.

Forward-Looking Statements

This press release includes “forward-looking

statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform

Act of 1995. Forward-Looking statements may be identified by the use of words such as “estimate,” “plan,” “project,”

“forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,”

“target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical

matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not

limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals

for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to maintain

compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and

the amount of capital required to complete the FDA pivotal trial and early commercialization; the Acclaim CI being the first to market

fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of

the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals

in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI’s PMA submission

to the FDA; the size of Envoy Medical’s addressable market, operational performance, future market conditions or economic performance

and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical.

The forward-looking statements contained in this press release reflect Envoy Medical’s current views about future events and are subject

to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ

significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will

happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties,

including, but not limited to changes in the market price of shares of Envoy Medical’s Class A Common Stock; changes in or removal of

Envoy Medical’s shares inclusion in any index; Envoy Medical’s success in retaining or recruiting, or changes required in, its officers,

key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the

clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure

to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions

in relationships with Envoy Medical’s suppliers, or disruptions in Envoy Medical’s own production capabilities for some of the key components

and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes

in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes

in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical’s key intellectual property

rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and

other international conflicts; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary

Note Regarding Forward-Looking Statements” in the Annual Report on Form 10-K filed by Envoy Medical on March 23, 2026, and in other

reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical’s assumptions prove incorrect, actual results

could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy

Medical’s good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update

or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future

events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance

on any forward-looking statements, which are based only on information currently available to Envoy Medical.

Investor Contact:

Phil Carlson

KCSA Strategic Communications

O: 212.896.1233

E: Envoy@kcsa.com

Media Contact:

Anne Donohoe

KCSA Strategic Communications

O: 732-620-0033

E: Envoy@kcsa.com

ENVOY MEDICAL, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

December 31,

2025

2024

Current assets:

Cash

$ 3,739

$ 5,483

Accounts receivable, net

Other receivable

780

Inventories

1,546

1,708

Prepaid expenses and other current assets

941

887

Total current assets

6,279

8,896

Property and equipment, net

1,035

1,275

Operating lease right-of-use asset (related party)

886

879

Prepaid expenses and other assets

358

488

Total assets

$ 8,558

$ 11,538

Liabilities, mezzanine equity, and stockholders’ deficit

Current liabilities:

Accounts payable

$ 2,920

$ 1,652

Accrued expenses

7,639

3,713

Accrued interest (related party)

703

Other current liabilities

518

573

Forward purchase agreement warrant liability

472

Product warranty liability, current portion

287

282

Operating lease liability, current portion (related party)

174

143

Total current liabilities

11,562

7,538

Term loans payable (related party)

18,716

Product warranty liability, net of current portion

1,605

1,771

Operating lease liability, net of current portion (related party)

745

802

Private warrant liability

5,835

Publicly traded warrant liability

551

662

Other liability

891

Total liabilities

20,325

30,380

Commitments and contingencies

Mezzanine equity

Warrants issued to placement agent

391

Stockholders’ deficit

Series A Preferred Stock, $0.0001 par value; 100,000,000 shares authorized and 10,000,000 shares designated as of December 31, 2025 and December 31, 2024; 4,126,667 shares issued and outstanding as of December 31, 2025 and December 31, 2024

Class A Common Stock, $0.0001 par value; 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 28,934,960 shares issued and outstanding as of December 31, 2025 and 21,326,609 shares issued and outstanding as of December 31, 2024

Additional paid-in capital

301,355

266,013

Accumulated deficit

(313,396 )

(284,734 )

Accumulated other comprehensive loss

(120 )

(123 )

Total stockholders’ deficit

(12,158 )

(18,842 )

Total liabilities, mezzanine equity, and stockholders’ deficit

$ 8,558

$ 11,538

ENVOY MEDICAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

Year Ended

December 31,

2025

2024

Net revenues

$ 241

$ 225

Costs and operating expenses:

Cost of goods sold

874

742

Research and development

12,486

10,179

Sales and marketing

1,220

1,734

General and administrative

7,931

6,826

Total costs and operating expenses

22,511

19,481

Operating loss

(22,270 )

(19,256 )

Other income (expense):

Change in fair value of forward purchase agreement put option liability

103

Change in fair value of forward purchase agreement warrant liability

534

411

Change in fair value of forward purchase agreement warrant liability due to extension

(24 )

(881 )

Loss on offering and change in fair value of private warrant liability

(494 )

Change in fair value of publicly traded warrant liability

111

(330 )

Interest expense, related party

(1,590 )

(816 )

Other expense, net

(23 )

(26 )

Total other income (expense), net

(1,486 )

(1,539 )

Net loss

(23,756 )

(20,795 )

Induced conversion of Series A Preferred Stock into Class A Common Stock

(1,162 )

Deemed dividend on waiver of restriction on Class A Common Stock

(495 )

Cumulative preferred dividends

(4,906 )

(5,521 )

Net loss attributable to common stockholders, basic and diluted

$ (28,662 )

$ (27,973 )

Net loss per share attributable to common stockholders, basic and diluted

$ (1.23 )

$ (1.49 )

Weighted-average Class A Common Stock outstanding, basic and diluted

23,259,598

18,790,448

Other comprehensive income (loss):

Foreign currency translation adjustment

(5 )

Other comprehensive income (loss)

(5 )

Comprehensive loss

$ (23,753 )

$ (20,800 )

ENVOY MEDICAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

Year Ended

December 31,

2025

2024

Cash flows from operating activities

Net loss

$ (23,756 )

$ (20,795 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

302

173

Interest expense and amortization of debt discount on Term Loans (related party)

1,590

816

Stock-based compensation for services

Amortization of prepaid insurance

964

1,047

Stock-based compensation

657

562

Loss on offering and change in fair value of private warrant liability

494

Change in fair value of publicly traded warrant liability

(111 )

330

Change in fair value of forward purchase agreement warrant liability

(534 )

(411 )

Change in fair value of forward purchase agreement put option liability

(103 )

Change in fair value of forward purchase agreement warrant liability due to extension

881

Net change in operating lease right-of-use assets and liability (related party)

206

113

Change in inventory reserve

Changes in operating assets and liabilities:

Accounts receivable, net

Other receivable

761

(604 )

Inventories

126

(380 )

Prepaid expenses and other current assets

(8 )

Accounts payable

1,385

(19 )

Operating lease liability (related party)

(239 )

(145 )

Accrued expenses

839

(241 )

Product warranty liability

(161 )

(181 )

Other liability

(868 )

891

Net cash used in operating activities

(18,201 )

(17,949 )

Cash flows from investing activities

Purchases of property and equipment

(179 )

(980 )

Net cash used in investing activities

(179 )

(980 )

Cash flows from financing activities

Payments on insurance financing loans

(827 )

(916 )

Proceeds from the issuance of Term Loans (related party)

10,000

20,000

Dividends paid to stockholders of Series A Preferred Stock

(1,819 )

(2,447 )

Payment made for extinguishment of Term Loans (related party)

(100 )

Proceeds from the issuance of Class A Common Stock from ATM offering

414

Proceeds from issuance of Class A Common Stock under employee stock purchase plan

184

Proceeds from exercise of forward purchase agreement warrants

3,111

1,815

Proceeds from the issuance of Class A Common Stock and Investor Warrants from registered direct offering

6,500

Offering costs from the issuance of Class A Common Stock and Investor Warrants from registered direct offering

(768 )

Deferred offering costs

(62 )

Proceeds from the issuance of Class A Common Stock associated with forward purchase agreement, net of transaction costs

1,683

Net cash provided by financing activities

16,633

20,198

Effect of exchange rate changes on cash

(5 )

Net (decrease) increase in cash

(1,744 )

1,264

Cash, beginning of year

5,483

4,219

Cash, end of year

$ 3,739

$ 5,483

Supplemental disclosures of cash flow information:

Cash paid for interest

$ 36

$ 41

Non-cash investing and financing activities:

Accrued and unpaid dividends on Series A Preferred Stock

$ 3,087

$ 3,074

Financing of prepaid insurance

$ 772

$ 843

Issuance of Term Loan Warrants (related party)

$ 1,570

$ 1,397

Accrued interest capitalized into term loans payable (related party)

$ 800

$ -

Modification of forward purchase agreement warrant

$ 62

$ 94

Lease liabilities arising from obtaining right-of-use assets

$ 121

$ 528

Extinguishment of excess warrant liability upon exercise of forward purchase agreement warrant

$ -

$ 96

Waiver of accrued dividends associated with Sponsor Support Agreement

$ -

$ 3,733

Deemed dividend on waiver of restriction on Class A Common Stock

$ -

$ 495

Induced conversion of Series A Preferred Stock to Class A Common Stock

$ -

$ 1,162

Property and equipment purchased on account

$ -

$ 117

Modification of Term Loan Warrants (related party)

$ 1,455

$ -

Deemed capital contribution associated with the extinguishment of Term Loans (related party)

$ 27,883

$ -

Issuance of Placement Agent Warrants

$ 391

$ -

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 23, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 23, 2026

Entity File Number

001-40133

Entity Registrant Name

ENVOY MEDICAL, INC.

Entity Central Index Key

0001840877

Entity Tax Identification Number

86-1369123

Entity Incorporation, State or Country Code

Entity Address, Address Line One

4875 White Bear Parkway

Entity Address, City or Town

White Bear Lake

Entity Address, State or Province

Entity Address, Postal Zip Code

55110

City Area Code

877

Local Phone Number

900-3277

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Class A Common Stock, par value $0.0001 per share

Title of 12(b) Security

Class A Common Stock, par value $0.0001 per share

Trading Symbol

COCH

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share

Title of 12(b) Security

Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share

Trading Symbol

COCHW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=COCH_ClassCommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=COCH_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: